Several reports have shown that the elimination of the HCV by interferon (IFN)-based therapy suppresses the development of HCC; the cumulative rate of carcinogenesis after an SVR is reported to be 2.3–8.8% at 5 years and 3.1–11.1% at 10 years, depending on patient characteristics [22]. The gene discussed is IFNA1; the disease is hepatocellular carcinoma.